# EDGAR Filing Document

**Accession Number:** 0001740279
**File Stem:** 0001193125-26-126224
**Filing Date:** 2026-3
**Character Count:** 5726
**Document Hash:** 54aff19aab075a578107b0295ab88403
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-126224.hdr.sgml**: 20260326

**ACCESSION NUMBER**: 0001193125-26-126224

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 9

**FILED AS OF DATE**: 20260326

**DATE AS OF CHANGE**: 20260326

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IN8BIO, INC.
- **CENTRAL INDEX KEY:** 0001740279
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 825462585
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39692
- **FILM NUMBER:** 26798187

**BUSINESS ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118
- **BUSINESS PHONE:** (646) 600-6438

**MAIL ADDRESS:**
- **STREET 1:** EMPIRE STATE BUILDING
- **STREET 2:** 350 5TH AVENUE, SUITE 5330
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Incysus Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20180510

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**SCHEDULE 14A** 

**Proxy Statement Pursuant to Section 14(a) of the** 

**Securities Exchange Act of 1934** 

**(Amendment No.)** 

Filed by the Registrant ☒

Filed by a party other than the Registrant ☐

Check the appropriate box:

☐ Preliminary Proxy Statement

☐ **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** 

☐ Definitive Proxy Statement

☒ Definitive Additional Materials

☐ Soliciting Material Pursuant to §240.14a-12

**IN8bio, Inc.** 

**(Name of Registrant as Specified In Its Charter)** 

**(Name of Person(s) Filing Proxy Statement, if Other Than The Registrant)** 

Payment of Filing Fee (Check the appropriate box):

☒ No fee required.

☐ Fee paid previously with preliminary materials.

☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

------

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![LOGO](g62125dsp1.jpg) <br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;P.O. BOX 8016, CARY, NC 27512-9903<br>![LOGO](g62125dsp1aa.jpg) <br>| ![LOGO](g62125dsp1dd.jpg) |

---

---

| | | |
|:---|:---|:---|
| <br>**IN8bio, Inc.**<br>**Annual Meeting of Stockholders**<br>Thursday, May 7, 2026 9:00 AM, Eastern Time<br>Annual Meeting to be held live via the internet - please visit www.proxydocs.com/INAB for more details<br>**You must register to attend the meeting online and/or participate at www.proxydocs.com/INAB**<br>**For a convenient way to view proxy materials, VOTE, and obtain instructions to attend the meeting online go to www.proxydocs.com/INAB**<br>**To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.**<br>This communication presents only an overview of the more complete proxy materials that are available to you on the internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.<br>Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.<br>If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before April 27, 2026. | ![LOGO](g62125dsp1g.jpg) <br>| <br>**Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K**<br>**Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On May 7, 2026 For Stockholders of Record as of March 18, 2026**<br>**To order paper materials, use one of the following methods.**<br>![LOGO](g62125dsp1a.jpg) <br>**Internet:**<br> **www.investorelections.com/INAB**<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ![LOGO](g62125dsp1b.jpg) <br> **Call:**<br> **1-866-648-8133**<br>![LOGO](g62125dsp1e.jpg) <br> **Email:**<br> **paper@investorelections.com**<br>\* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.<br>![LOGO](g62125dsp1ff.jpg)  |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Have the 12 digit control number located in the box above available when you access the website and follow the instructions. |
| **SEE REVERSE FOR FULL AGENDA** |  |  |

---

Copyright© 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved

------

---

| | |
|:---|:---|
| ![LOGO](g62125dsp1.jpg) | **IN8bio, Inc. Annual Meeting of Stockholders** |

---

**FOR** ALL NOMINEES FOR DIRECTOR IN PROPOSAL 1 AND **FOR** EACH OF PROPOSAL 2 AND PROPOSAL 3

 <br> **PROPOSAL**<br>

---

| | |
|:---|:---|
| 1. | To elect the two nominees for Class II directors named in the attached proxy statement, each to serve until our 2029 Annual Meeting of Stockholders. |
|  | 1.01 Peter Brandt |
|  | 1.02 Corinne Epperly |
| 2. | To ratify the selection of CohnReznick LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. |
| 3. | To approve our Amended and Restated 2026 Equity Incentive Plan. |

---